Case Reports
Vol. 71 No. 2 (2019)
Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 31 December 2017
Accepted: 6 September 2018
Accepted: 6 September 2018
1431
Views
917
Downloads
Authors
Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far.
Downloads
Download data is not yet available.
Citations
How to Cite
1.
Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case. Reumatismo [Internet]. 2019 Jul. 9 [cited 2026 Feb. 2];71(2):99-102. Available from: https://www.reumatismo.org/reuma/article/view/1115
